Drug news
Jakafi/Jakavi enters Phase III for Pancreatic Cancer-Incyte + Novartis
An agreement has been reached with the FDA and Incyte Corporation to conduct a Phase III registrational studies of Jakafi/Jakavi (ruxolitinib) for the second-line treatment of Pancreatic Cancer under a Special Protocol Assessment (SPA) designation. The study will enroll participants with the characteristics identified by the Phase II RECAP patient population. Additionally, Incyte will not need to have a companion diagnostic. The Phase III study is expected to begin enrolment in the first quarter of 2014.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins